Literature DB >> 9143411

Pathological and genetic correlates of apoptosis in the progression of colorectal neoplasia.

N Hawkins1, J Lees, R Hargrave, T O'Connor, A Meagher, R Ward.   

Abstract

PURPOSE: Apoptosis is commonly observed in a variety of human tumors, and some of the genetic events which control this process have been identified in vitro. The aim of this study was to determine the frequency of apoptosis in colorectal neoplasms and to examine its relationship to a number of pathological parameters, to the presence of mutations in the p53 tumor suppressor gene, and to overexpression of the bcl-2 oncoprotein.
METHODS: A total of 109 colorectal neoplasms (26 adenomas 83 carcinomas) were examined. An in situ end-labelling assay was used to detect apoptosis in paraffin-embedded tumor sections, and scores were determined by light microscopy. The p53 and bcl-2 status were determined by immunohistochemistry.
RESULTS: Apoptotic frequency increased with tumor progression. Normal mucosa contained significantly fewer apoptotic cells than adenomas or carcinomas. Similarly adenomas showed less apoptosis than carcinomas, and the frequency of apoptosis increased with Dukes' stage. Overall, changes in apoptotic frequency were inversely related to the level of bcl-2 expression, but were not related to the p53 status of the tumors.
CONCLUSIONS: The frequency of apoptosis in colorectal neoplasia appears to increase in the course of tumor progression in association with a decline in bcl-2 expression, but is not influenced by p53 gene mutations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143411     DOI: 10.1159/000218025

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  7 in total

1.  Correlation of bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia.

Authors:  H A Saleh; H Jackson; G Khatib; M Banerjee
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

2.  Correlation between pathological features and protein expressions of TfR1, VEGF and MMP-9 in patients with osteosarcoma.

Authors:  Chujie Bai; Xiuli Ma; Xinyu Wang; Xiaoya Chen
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

Review 3.  Apoptotic pathways as a therapeutic target for colorectal cancer treatment.

Authors:  Aman M Abraha; Ezra B Ketema
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

4.  Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer.

Authors:  Javier de Oca; Daniel Azuara; Raquel Sanchez-Santos; Matilde Navarro; Gabriel Capella; Victor Moreno; Anna Sola; Georgina Hotter; Sebastiano Biondo; Alfonso Osorio; Joan Martí-Ragué; Antoni Rafecas
Journal:  Int J Colorectal Dis       Date:  2007-09-04       Impact factor: 2.571

5.  Detection of apoptotic cells in human colorectal cancer by two different in situ methods: antibody against single-stranded DNA and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) methods.

Authors:  I Watanabe; M Toyoda; J Okuda; T Tenjo; K Tanaka; T Yamamoto; H Kawasaki; T Sugiyama; Y Kawarada; N Tanigawa
Journal:  Jpn J Cancer Res       Date:  1999-02

6.  Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways.

Authors:  Ian T Saunders; Hina Mir; Neeraj Kapur; Shailesh Singh
Journal:  Cancer Cell Int       Date:  2019-04-15       Impact factor: 5.722

Review 7.  BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy.

Authors:  Prashanthi Ramesh; Jan Paul Medema
Journal:  Apoptosis       Date:  2020-06       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.